Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
120.27
-4.06 (-3.27%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $622.10M in the quarter ending September 30, 2024, with 24.72% growth. This brings the company's revenue in the last twelve months to $2.24B, up 25.72% year-over-year. In the year 2023, Neurocrine Biosciences had annual revenue of $1.89B with 26.76% growth.
Revenue (ttm)
$2.24B
Revenue Growth
+25.72%
P/S Ratio
5.36
Revenue / Employee
$1,602,000
Employees
1,400
Market Cap
12.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fresenius Medical Care AG | 20.80B |
Smith & Nephew | 5.64B |
Catalent | 4.38B |
AptarGroup | 3.57B |
Teleflex | 3.01B |
Royalty Pharma | 2.24B |
Medpace Holdings | 2.07B |
Sarepta Therapeutics | 1.50B |
NBIX News
- 1 day ago - Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance - PRNewsWire
- 21 days ago - Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade) - Seeking Alpha
- 22 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit - PRNewsWire
- 7 weeks ago - Neurocrine's experimental drug misses primary goal in schizophrenia trial - Reuters
- 7 weeks ago - Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia - PRNewsWire